CN1182588A - 舒布硫胺在制备用于治疗某些精神运动性和心理智力性疾病的药物组合物中的用途 - Google Patents
舒布硫胺在制备用于治疗某些精神运动性和心理智力性疾病的药物组合物中的用途 Download PDFInfo
- Publication number
- CN1182588A CN1182588A CN97122552A CN97122552A CN1182588A CN 1182588 A CN1182588 A CN 1182588A CN 97122552 A CN97122552 A CN 97122552A CN 97122552 A CN97122552 A CN 97122552A CN 1182588 A CN1182588 A CN 1182588A
- Authority
- CN
- China
- Prior art keywords
- sulbutiamine
- treatment
- psychological
- preparation
- intelligence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 12
- 201000010099 disease Diseases 0.000 title claims description 11
- 239000000203 mixture Substances 0.000 title claims 3
- 230000003340 mental effect Effects 0.000 title 1
- CKHJPWQVLKHBIH-ZDSKVHJSSA-N sulbutiamine Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(/C)=C(/CCOC(=O)C(C)C)SS\C(CCOC(=O)C(C)C)=C(\C)N(C=O)CC1=CN=C(C)N=C1N CKHJPWQVLKHBIH-ZDSKVHJSSA-N 0.000 claims abstract description 28
- 229960003211 sulbutiamine Drugs 0.000 claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 6
- 230000037047 psychomotor activity Effects 0.000 claims description 6
- 230000000881 depressing effect Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 230000000698 schizophrenic effect Effects 0.000 claims description 3
- 230000035807 sensation Effects 0.000 claims description 3
- 210000000088 lip Anatomy 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 abstract description 5
- 208000007848 Alcoholism Diseases 0.000 abstract description 3
- 201000007930 alcohol dependence Diseases 0.000 abstract description 3
- 208000024732 dysthymic disease Diseases 0.000 abstract description 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000001149 cognitive effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 239000003176 neuroleptic agent Substances 0.000 description 3
- 230000000701 neuroleptic effect Effects 0.000 description 3
- 238000012030 stroop test Methods 0.000 description 3
- 239000011691 vitamin B1 Substances 0.000 description 3
- 235000010374 vitamin B1 Nutrition 0.000 description 3
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 206010006100 Bradykinesia Diseases 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- -1 glossettes Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000012034 trail making test Methods 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preliminary Treatment Of Fibers (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
舒布硫胺在制备用于治疗某些精神运动性和心理智力性的疾病的药物组合物中的用途,这类症状在帕金森氏病人中、功能减退型精神***症患者中、酗酒者中、严重抑郁症患者和精神抑郁者中能观察到。
Description
本发明涉及舒布硫胺在制备用于治疗某些精神运动性和心理智力性疾病的药物组合物中的用途,这类疾病的特征是对于需要感觉和精神概念总动员的行为和智力的响应延迟、迟缓和阻抑。在帕金森氏病人中、功能减退型精神***症患者中、酗酒者中、严重抑郁症患者中和精神抑郁者中尤其能观察到这些病症。
舒布硫胺是一种在文献中已知的并且作过描述的有效成分。特殊药物专利5921M记述这种产品是一种有维生素B1活性的制剂,能够升高维生素B1在血中的含量,并且能够对于所有维生素B1缺乏症起治疗作用。
特殊药物专利5921M也提到为了这类治疗目的,将这种产品以片剂的形式使用,每单位剂量含5-50mg的这种产品。
最后,比利时专利BE845 260描述了舒布硫胺促精神兴奋的性质,这种性质能够拮抗镇静药或精神安定药的精神抑制作用。
对于这一点,Vidal推荐使用舒布硫胺来治疗活力衰退和感情淡漠的某些生理上或心理上的抑制状态。
本申请人现在已经证明,使用舒布硫胺药物能够治愈第一段所述的帕金森氏病人中的、功能减退型精神***症患者中的、酒精戒断后住院治疗的酗酒者中的、精神抑郁者或其他严重抑郁症的病人中的精神运动性和心理智力性的病症。
在针对这些病人的不同研究中,舒布硫胺已经在各种情形中使精神运动迟缓、运动受抑制、智力谋划障碍以及执行功能障碍的患者得到恢复。
根据本发明的这种药物组合物含有舒布硫胺,可以单独地或与一种或几种惰性、无毒的药物可接受载体结合使用。用于治疗这些患者中精神运动性和心理智力性疾病的药物使用本发明的舒布硫胺制备,其可以呈在药物学上适于给药的形式,采用口服,非肠道给药,透皮给药、鼻内、直肠内或舌下的途径给药,尤其可以呈片剂、舌下含片、glossettes、明胶胶囊、胶囊、栓剂、皮肤贴剂、颊部贴剂,等等。
用药量按照病人的年龄和体重、给药途径、治疗适应症的性质和相关治疗而变化,范围为每天口服400-800mg。
临床研究
实施例1:舒布硫胺对于酒精依赖且戒断酒精的病人的心理认知演变的效果
这个研究是对在进行酒精戒断治疗之后的所有住院的酒精依赖病人实施的。
这些病人分成平行的二组并且在双盲的条件下,或者使用舒布硫胺,或者使用安慰剂治疗6个星期,治疗按照随机的规则分派。
借助下述实验评价治疗的效果:
1-认知和执行功能和注意力,
- 被唤起的认知潜力,
- Stroop试验
- 画轨迹测验(trail making test)
- MADRS表(注意力集中困难)。
2-记忆功能:
-Benton试验,
-Rey图形
-Wechsler表。
3-情绪和焦虑
-MADRS表(感情迟钝,活力衰退),
-HARS表(退缩),
-Beck表(活力衰退)。
对于这些依赖酒精戒断酒精的病人用舒布硫胺治疗之后,观察到在认知和记忆功能和注意力方面有显著的改善。
实施例2:舒布硫胺对帕金森氏病人客观和主观的认知迟缓以及疲劳感的效果
这个研究是对大量患先天性帕金森氏病人进行的,采用L-多巴和/或多巴胺能激动剂治疗,进入研究时是稳定的,运动状态没有严重的起伏并且没有痴呆的迹象。
这些病人分成平行的二组并且在双盲的条件下,或者使用舒布硫胺,或者使用安慰治疗8个星期,治疗按照随机的规则分派。
通过以下的实验评价治疗的效果:
1-认知功能、注意力、语言、思维能力和运动迟缓:
-15目标试验,
-Stroop试验,
-MADRS语言表(注意力集中困难),
-语言流畅的试验
-画轨迹试验,
2-执行功能:
-OMO(odd man out)试验,
-Wais-R。
3-记忆功能:
-Grober和Buschke试验。
4-疲劳的感觉:
-疲劳的自我评价。
5-情绪:
-MADRS表(感情迟钝,活力衰退)。
对于帕金森氏病人,使用舒布硫胺治疗,观察到认知、执行和记忆功能改善、疲劳感觉减少。
实施例3:舒布硫胺对于精神抑郁病人的抑制症状的效果
这个研究对不住院的有运动、思维能力和认知抑制和迟缓症状的精神抑郁症病人进行。
这些病人分成平行的二组并且在双盲的条件下,或者使用舒布硫胺,或者使用安慰剂治疗8个星期,治疗按照随机的规则分派。
治疗的效果用以下各项评价:
1-运动、语言、思维能力和认知迟缓:
-迟缓的Widlocher表
-语言记时法,
-语言的声音分析。
2-情绪和焦虑:
-MADRS表(感情迟钝,活力衰退),
-Abrams-Taylor表,
-Widlocher表。
使用舒布硫胺治疗精神抑郁病人,观察到其运动、语言和认知迟缓有根本性的改善。
实施例4:舒布硫胺对已经使用三环抗抑郁剂治疗的严重抑郁症病人的抑制症状的效果
这个研究是对因严重抑郁状态而住院并且用可变剂量的氯丙咪嗪治疗的病人实施的。
这些病人分成平行的二组并且在双盲的条件下,或者使用舒布硫胺,或者使用安慰剂治疗8个星期,治疗按照随机的规则分派。
治疗的效果用以下各项评价:
1-运动、思维能力和认知迟缓:
-Sheehan无能力标准,
-HARS表(缺乏兴趣,记忆障碍),
-MADRS表(注意力集中困难,活力衰退),
-Widlocher表,
-Norris视觉类似物表
-疲劳的自我评价。
2-情绪和焦虑。
-MADRS表(感情迟钝),
-HARS表,
-Widlocher表。
在使用舒布硫胺治疗的病人组中,观察到抑制症状、特别是认知功能得到改善。
实施例5:舒布硫胺对已经使用精神安定药治疗的功能减退型精神***症病人的抑制症状的改善
这个研究是对已经使用精神安定药在门诊治疗的功能减退型精神***症病人实施的。
这些病人分成平行的二组并且在双盲的条件下,或者使用舒布硫胺,或者使用安慰剂治疗12个星期,治疗按照随机的规则分派。
这个治疗用以下各项进行评价:
1-认知功能:
-PSNSS表,
-划规迹试验,
-Stroop试验,
-Norris视觉类似物表
-MADRS表(注意力集中困难,活力衰退)。
2-执行功能:
-Wisconsin卡片分类试验,
3-记忆功能:
-Grober和Buschke试验,
4-精神***症抗拒体征:
-PANBSS表。
5-生活的质量:
-Heinrichs’生活质量标准。
在使用舒布硫胺治疗的病人组中观察到精神***症体征消失,同时生活质量有所改善。
Claims (3)
1.舒布硫胺在制备用于治疗某些精神运动性和心理智力性的疾病的药物组合物中的用途,这类疾病见于帕金森氏病人中、功能减退型精神***症患者中、酗酒者中、严重抑郁症患者和精神抑郁者中。
2.如权利要求1所述的舒布硫胺制备药物组合物的用途,所述组合物用于治疗精神运动性和心理智力性的疾病,这些疾病的特点是对于需要感觉和精神概念总动员的行为和智力的响应延迟、迟缓和阻抑。
3.如权利要求2所述的舒布硫胺制备药物组合物的用途,所述组合物可以单独含有该活性成分或将其与一种或几种惰性、无毒中的药物可接受载体结合使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9612112 | 1996-10-04 | ||
FR9612112A FR2754178B1 (fr) | 1996-10-04 | 1996-10-04 | Utilisation de la sulbutiamine pour l'obtention de compositions pharmaceutiques utiles dans le traitement de certains troubles psychomoteurs et psycho-intellectuels |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1182588A true CN1182588A (zh) | 1998-05-27 |
CN1091370C CN1091370C (zh) | 2002-09-25 |
Family
ID=9496363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97122552A Expired - Fee Related CN1091370C (zh) | 1996-10-04 | 1997-09-29 | 舒布硫胺在制备用于治疗某些精神运动性和心理智力性疾病的药物组合物中的用途 |
Country Status (17)
Country | Link |
---|---|
US (1) | US5863925A (zh) |
EP (1) | EP0834316B1 (zh) |
JP (1) | JP4234218B2 (zh) |
CN (1) | CN1091370C (zh) |
AT (1) | ATE216884T1 (zh) |
AU (1) | AU716329B2 (zh) |
BR (1) | BR9704964A (zh) |
CA (1) | CA2217463C (zh) |
DE (1) | DE69712287T2 (zh) |
DK (1) | DK0834316T3 (zh) |
ES (1) | ES2176642T3 (zh) |
FR (1) | FR2754178B1 (zh) |
HU (1) | HU227542B1 (zh) |
NO (1) | NO313684B1 (zh) |
NZ (1) | NZ328915A (zh) |
PT (1) | PT834316E (zh) |
ZA (1) | ZA978879B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030070150A (ko) * | 2001-01-31 | 2003-08-27 | 화이자 프로덕츠 인크. | Pde4 이소자임 억제제로서 유용한 에테르 유도체 |
NZ530158A (en) * | 2002-12-20 | 2005-11-25 | Therakos Inc | Irradiation chamber |
US20070185141A1 (en) * | 2006-02-09 | 2007-08-09 | Tim Patterson | Thiamine composition for enhancement of physical and mental energy, and related method |
WO2014172372A1 (en) | 2013-04-15 | 2014-10-23 | Northwestern University | Treatment for dopaminergic disorders |
-
1996
- 1996-10-04 FR FR9612112A patent/FR2754178B1/fr not_active Expired - Fee Related
-
1997
- 1997-09-29 CN CN97122552A patent/CN1091370C/zh not_active Expired - Fee Related
- 1997-10-01 JP JP26831697A patent/JP4234218B2/ja not_active Expired - Fee Related
- 1997-10-02 CA CA002217463A patent/CA2217463C/fr not_active Expired - Fee Related
- 1997-10-02 BR BR9704964A patent/BR9704964A/pt not_active Application Discontinuation
- 1997-10-02 NO NO19974551A patent/NO313684B1/no not_active IP Right Cessation
- 1997-10-03 DE DE69712287T patent/DE69712287T2/de not_active Expired - Lifetime
- 1997-10-03 HU HU9701606A patent/HU227542B1/hu not_active IP Right Cessation
- 1997-10-03 US US08/943,564 patent/US5863925A/en not_active Expired - Lifetime
- 1997-10-03 EP EP97402320A patent/EP0834316B1/fr not_active Expired - Lifetime
- 1997-10-03 PT PT97402320T patent/PT834316E/pt unknown
- 1997-10-03 AU AU39928/97A patent/AU716329B2/en not_active Ceased
- 1997-10-03 ZA ZA9708879A patent/ZA978879B/xx unknown
- 1997-10-03 ES ES97402320T patent/ES2176642T3/es not_active Expired - Lifetime
- 1997-10-03 AT AT97402320T patent/ATE216884T1/de active
- 1997-10-03 DK DK97402320T patent/DK0834316T3/da active
- 1997-10-06 NZ NZ328915A patent/NZ328915A/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DK0834316T3 (da) | 2002-08-05 |
CA2217463C (fr) | 2003-04-01 |
EP0834316B1 (fr) | 2002-05-02 |
FR2754178A1 (fr) | 1998-04-10 |
EP0834316A1 (fr) | 1998-04-08 |
ES2176642T3 (es) | 2002-12-01 |
NO974551L (no) | 1998-04-06 |
HU9701606D0 (en) | 1997-11-28 |
AU3992897A (en) | 1998-04-09 |
DE69712287T2 (de) | 2002-12-12 |
US5863925A (en) | 1999-01-26 |
CA2217463A1 (fr) | 1998-04-04 |
BR9704964A (pt) | 1998-10-27 |
AU716329B2 (en) | 2000-02-24 |
NO313684B1 (no) | 2002-11-18 |
JP4234218B2 (ja) | 2009-03-04 |
ATE216884T1 (de) | 2002-05-15 |
NZ328915A (en) | 2000-08-25 |
PT834316E (pt) | 2002-08-30 |
JPH10130151A (ja) | 1998-05-19 |
HUP9701606A2 (hu) | 1998-06-29 |
CN1091370C (zh) | 2002-09-25 |
NO974551D0 (no) | 1997-10-02 |
ZA978879B (en) | 1998-04-17 |
HUP9701606A3 (en) | 1999-07-28 |
FR2754178B1 (fr) | 2002-08-23 |
HU227542B1 (en) | 2011-08-29 |
DE69712287D1 (de) | 2002-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1147767A (zh) | 5-羟色胺拮抗剂的新应用 | |
AU780817B2 (en) | Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone | |
CN1561994A (zh) | 治疗类风湿性关节炎和免疫性疾病的含青蒿提取物药物组合物 | |
CN1091370C (zh) | 舒布硫胺在制备用于治疗某些精神运动性和心理智力性疾病的药物组合物中的用途 | |
CN1698873A (zh) | 一种心力丸口腔崩解片及其制备方法 | |
CN1414847A (zh) | 含吡喹酮的缓释抗蠕虫组合物 | |
CN1055392C (zh) | 治疗牛皮癣的药物组合物及其药用 | |
CN1411861A (zh) | 治疗急性筋伤的药物及其制备方法 | |
CN115624543B (zh) | 治疗偏头痛的药物、药物组合物、其制备方法和制药用途 | |
CN1209162C (zh) | 治疗痤疮、黄褐斑的药物组合物 | |
CN1040063C (zh) | 葡萄糖酸锌在制备平喘镇咳药中的应用 | |
CN1668313A (zh) | 用于药物诱导的神经病的药物组合物 | |
CN1663600A (zh) | 银杏叶提取物和促进脑代谢的药物组成的复方制剂及其应用 | |
CN1724036A (zh) | 促进体内分泌褪黑激素的药物以及相关中药组合物的应用 | |
CN1679673A (zh) | 板蓝根滴丸及其制备方法 | |
CN1372950A (zh) | 治疗颈椎病的药物及制备方法 | |
CN1872187A (zh) | 一种含有黄芪药物组合物在制备治疗慢性脑供血不足药物中的应用 | |
CN1876083A (zh) | 一种活血壮筋胶囊及其制备工艺 | |
CN1634145A (zh) | 一种治疗脑炎、肝昏迷的醒脑静滴丸及其制备方法 | |
CN1751596A (zh) | 提高抗消化道感染免疫的中药保健食品及软胶囊和制备方法 | |
CN1200725C (zh) | 一种治疗脑功能障碍的中药制剂及其制备方法 | |
CN1149096C (zh) | 治疗耐药性结核病的药物 | |
CN1531954A (zh) | 一种治疗抑郁症的药物及其制备方法 | |
CN1395933A (zh) | 治疗心脑血管疾病的药物 | |
CN1099873C (zh) | 杨瘌子作为制备治疗骨关节病的药的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Applicant after: Laboratoires Therwill Applicant before: Adir Et Compagnie |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: ADIR ET CO. TO: SERVIER LAB |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20020925 Termination date: 20140929 |
|
EXPY | Termination of patent right or utility model |